104,401 results match your criteria Estrogen Therapy

Progestogen-mediated neuroprotection in central nervous system disorders.

Neuroendocrinology 2022 Jun 27. Epub 2022 Jun 27.

Neuroactive steroids can be synthetic or endogenous molecules produced by neuronal and glial cells, and peripheral glands. Examples include estrogens, testosterone, progesterone and its reduced metabolites such as 5-dihydroprogesterone and allopregnanolone. Steroids produced by neurons and glia target the nervous system and are called neurosteroids. Read More

View Article and Full-Text PDF

Pharmacotherapy in Cachexia: A Review of Endocrine Abnormalities and Steroid Pharmacotherapy.

J Pain Palliat Care Pharmacother 2022 Jun;36(2):117-131

Katarzyna Lacka,MD, PhD is with the Department of Endocrinology, Metabolism and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland.

Cachexia is a state of increased metabolism associated with high morbidity and mortality. Dysregulation of cytokines and hormone activity causes reduced protein synthesis and excessive protein breakdown. various treatments are available, depending on the primary disease and the patient's state. Read More

View Article and Full-Text PDF

A Preliminary Study on the Effects of Black Cohosh Preparations on Bone Metabolism of Rat Models With GnRH-a-Induced Peri-Menopausal Symptoms.

Front Endocrinol (Lausanne) 2022 9;13:854345. Epub 2022 Jun 9.

Department of Obstetrics and Gynecology, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou, China.

Background: Endometriosis (EMS) is a relapsing and estrogen-dependent disease. For endometriosis such as deep endometriosis and ovarian endometrioid cysts, surgery is the most effective treatment. Long-term follow-up showed that the recurrence rate of endometriosis after surgical treatment was high, so postoperative drugs were needed to reduce recurrence, and Gonadotropin-releasing hormone agonists (GnRH-a) were the most commonly used drug for postoperative management. Read More

View Article and Full-Text PDF

The Association Between Route of Post-menopausal Estrogen Administration and Blood Pressure and Arterial Stiffness in Community-Dwelling Women.

Front Cardiovasc Med 2022 10;9:913609. Epub 2022 Jun 10.

Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Background: Postmenopausal hormone therapy (HT) is associated with increased cardiovascular risk. Although the route of estrogen administration may play a role in mediating risk, previous studies have not controlled for concomitant progestin use.

Objective: To investigate the association between the route of estrogen therapy (oral or non-oral) HT use, without concomitant progestin, and blood pressure and arterial stiffness in postmenopausal women. Read More

View Article and Full-Text PDF

Preventing late recurrence in hormone receptor-positive early breast cancer: a review.

Eur J Cancer 2022 Jun 23;172:53-64. Epub 2022 Jun 23.

Breast Unit - Department of Medicine, The Royal Marsden NHS Foundation Trust, 203 Fulham Rd, Chelsea, London SW3 6JJ, United Kingdom. Electronic address:

Late recurrences are a key challenge for patients with early-stage oestrogen receptor-positive breast cancer, with the risk of disease relapse continuing steadily from 5 to more than 20 years after diagnosis. Five years of adjuvant endocrine therapy with tamoxifen or an aromatase inhibitor was shown many years ago to improve survival. More recently, the trials of extended adjuvant endocrine therapy for more than 5 years have shown a further small gain, but with an associated small risk of increased long-term toxicity including bone loss, cardiovascular impairment and impaired quality of life. Read More

View Article and Full-Text PDF

Update on prognostic and predictive biomarkers of breast cancer.

Semin Diagn Pathol 2022 Jun 18. Epub 2022 Jun 18.

Department of pathology, The Ohio State University Wexner Medical Center, Columbus OH. Electronic address:

Breast cancer represents a heterogeneous group of human cancer at both histological and molecular levels. Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) are the most commonly used biomarkers in clinical practice for making treatment plans for breast cancer patients by oncologists. Recently, PD-L1 testing plays an important role for immunotherapy for triple-negative breast cancer. Read More

View Article and Full-Text PDF

Gender-Affirming Hormone Therapy: What the Head and Neck Surgeon Should Know.

C Michael Haben

Otolaryngol Clin North Am 2022 Jun 22. Epub 2022 Jun 22.

Center for the Care of the Professional Voice, 980 Westfall road, Suite 1-127, Rochester, NY 14618, USA. Electronic address:

The use of gender-affirming hormone therapy is found almost universally in transgendered and nonbinary patients presenting for gender-affirming surgical procedures of the face, neck, and voice. Surgeons caring for this population need to be aware of the effects, reasonable expectations, and limitations as well as potential perioperative risks of both continuation and discontinuation of hormone therapy. Read More

View Article and Full-Text PDF

Tc-99m-tamoxifen: A novel diagnostic imaging agent for estrogen receptor-expressing breast cancer patients.

Diagn Interv Radiol 2022 May;28(3):275-284

Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

PURPOSE The aim of the study was to radiolabel, characterize, and perform in vitro and in vivo assessment of Technetium-99m (Tc-99m) tamoxifen for screening ER expressing lesions in breast cancer patients. METHODS In this study, tamoxifen has been radiolabeled with Tc-99m via Tc-99m-tricarbonyl core. The characterization and quality control tests of Tc-99m-tamoxifen were performed. Read More

View Article and Full-Text PDF

Ovarian Tissue-Based Hormone Replacement Therapy Recovers Menopause-Related Signs in Mice.

Yonsei Med J 2022 Jul;63(7):648-656

Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.

Purpose: In women, menopause manifests with a variety of symptoms related to sex-hormone deficiency. Supplementing steroid hormones with pharmacological drugs has been widely practiced. However, considering the possible complications associated with artificial hormone therapy, studies have been conducted to find an alternative to pharmacological hormone replacement therapy. Read More

View Article and Full-Text PDF

Influence of the anti-oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review.

Cancer Med 2022 Jun 24. Epub 2022 Jun 24.

Department of Endocrinology and Metabolism, Rigshospitalet, Copenhagen, Denmark.

Introduction: Breast cancer (BC) is a common type of cancer in women. Advances in therapy options have resulted in higher overall survival rates but side effects of cancer treatment are increasingly in the spotlight. The beneficial effects of anti-oestrogen therapy with tamoxifen and letrozole in the prevention of BC recurrence are well documented. Read More

View Article and Full-Text PDF

Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia.

Mol Clin Oncol 2022 Jul 1;17(1):119. Epub 2022 Jun 1.

Oncology Center, International Medical Center, King Saud Bin Abdul Aziz University for Health Sciences, King Abdullah International Medical Research Center, King Abdulaziz Medical City, Jeddah 21423, Kingdom of Saudi Arabia.

The addition of palbociclib (a cyclin-dependent kinase 4/6 inhibitor) to endocrine therapy (ET) has been shown to significantly improve progression-free survival (PFS) and overall survival (OS) among patients with hormone receptor-positive (HR) advanced breast cancer. The current study presents the local experience of using palbociclib at two cancer centers in Saudi Arabia. Electronic data of patients with metastatic HR and human epidermal growth factor receptor 2-negative breast cancer who progressed after prior ET and received at least one cycle of palbociclib plus ET, were retrospectively reviewed. Read More

View Article and Full-Text PDF

Role of Phytoestrogen-Rich Bioactive Substances ( L., L., L.) in Cardiovascular Disease Prevention in Postmenopausal Women: A Systematic Review and Meta-Analysis.

Nutrients 2022 Jun 14;14(12). Epub 2022 Jun 14.

Department of Virology with SARS Laboratory, Medical University of Lublin, 20-093 Lublin, Poland.

The aim of this report was to determine the impact of flaxseed, soy and red clover, and their bioactive substances on the lipid profile in postmenopausal women in cardiovascular diseases prevention. We used the following databases: MEDLINE (PubMed), EMBASE and the Cochrane Library. Meta-analysis indicates that the intake of flaxseed by postmenopausal women is associated with a statistically significant reduction in total cholesterol (TC) levels (weighted-mean difference (WMD) = -0. Read More

View Article and Full-Text PDF

Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line.

Molecules 2022 Jun 7;27(12). Epub 2022 Jun 7.

Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia.

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, having a poor prognosis and rapid metastases. TNBC is characterized by the absence of estrogen, progesterone, and human epidermal growth receptor-2 (HER2) expressions and has a five-year survival rate. Compared to other breast cancer subtypes, TNBC patients only respond to conventional chemotherapies, and even then, with limited success. Read More

View Article and Full-Text PDF

New Innovations for the Treatment of Vulvovaginal Atrophy: An Up-to-Date Review.

Medicina (Kaunas) 2022 Jun 6;58(6). Epub 2022 Jun 6.

Obstetrics and Gynecology Unit, IRCCS San Raffaele Hospital, Vita-Salute University, 20132 Milan, Italy.

Vulvovaginal atrophy (VVA) is a chronic progressive disease involving the female genital apparatus and lower urinary tract. This condition is related to hypoestrogenism consequent to menopause onset but is also due to the hormonal decrease after adjuvant therapy for patients affected by breast cancer. Considering the high prevalence of VVA and the expected growth of this condition due to the increase in the average age of the female population, it is easy to understand its significant social impact. Read More

View Article and Full-Text PDF

Stem Cell Biomarkers and Tumorigenesis in Gastric Cancer.

J Pers Med 2022 Jun 3;12(6). Epub 2022 Jun 3.

Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.

Stomach cancer has a high mortality, which is partially caused by an absence of suitable biomarkers to allow detection of the initiation stages of cancer progression. Thus, identification of critical biomarkers associated with gastric cancer (GC) is required to advance its clinical diagnoses and treatment. Recent studies using tracing models for lineage analysis of GC stem cells indicate that the cell fate decision of the gastric stem cells might be an important issue for stem cell plasticity. Read More

View Article and Full-Text PDF

Targeting Breast Cancer Stem Cells Using Naturally Occurring Phytoestrogens.

Int J Mol Sci 2022 Jun 18;23(12). Epub 2022 Jun 18.

Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.

Breast cancer therapies have made significant strides in improving survival for patients over the past decades. However, recurrence and drug resistance continue to challenge long-term recurrence-free and overall survival rates. Mounting evidence supports the cancer stem cell model in which the existence of a small population of breast cancer stem cells (BCSCs) within the tumor enables these cells to evade conventional therapies and repopulate the tumor, giving rise to more aggressive, recurrent tumors. Read More

View Article and Full-Text PDF

Antagonistic Pharmacological Interaction between Sirtuin Inhibitor Cambinol and Paclitaxel in Triple-Negative Breast Cancer Cell Lines: An Isobolographic Analysis.

Int J Mol Sci 2022 Jun 9;23(12). Epub 2022 Jun 9.

Department of Biochemistry and Molecular Biology, Medical University of Lublin, 20-093 Lublin, Poland.

Breast cancer (BC) is a heterogeneous disease with different intrinsic subtypes. The most aggressive subtype of BC-triple-negative breast cancer (TNBC) is characterized by high heterogeneity and metastasis rate, poor prognosis and lack of therapeutic targets due to the absence of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2. Targeted therapies have been approved for many other cancers and even other subtypes of BC, but treatment options for TNBC are still mainly limited to chemotherapy. Read More

View Article and Full-Text PDF

Hormonal and Genetic Regulatory Events in Breast Cancer and Its Therapeutics: Importance of the Steroidogenic Acute Regulatory Protein.

Biomedicines 2022 Jun 3;10(6). Epub 2022 Jun 3.

Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.

Estrogen promotes the development and survival of the majority of breast cancers (BCs). Aromatase is the rate-limiting enzyme in estrogen biosynthesis, and it is immensely expressed in both cancerous and non-cancerous breast tissues. Endocrine therapy based on estrogen blockade, by aromatase inhibitors, has been the mainstay of BC treatment in post-menopausal women; however, resistance to hormone therapy is the leading cause of cancer death. Read More

View Article and Full-Text PDF

Recent progress in antibody-based therapeutics for triple-negative breast cancer.

Expert Opin Drug Deliv 2022 Jun 23. Epub 2022 Jun 23.

State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China.

Introduction: Triple-negative breast cancer (TNBC) is a subtype of severely aggressive breast cancer that lacks the expression of oestrogen receptor (ER), progesterone receptor and human epidermal growth factor receptor 2 (HER2) and is highly metastatic and related to a poor prognosis. Current standard treatments are still limited to systemic chemotherapy, radiotherapy, and surgical resection. More effective treatments are urgently needed. Read More

View Article and Full-Text PDF

New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies.

Med Sci (Basel) 2022 May 25;10(2). Epub 2022 May 25.

Department of Clinical and Molecular Medicine, Sapienza University of Rome, 1035-1039 Rome, Italy.

Cardiovascular diseases are largely represented in patients with cancer and appear to be important side effects of cancer treatments, heavily affecting quality of life and leading to premature morbidity and death among cancer survivors. In particular, treatments for breast cancer have been shown to potentially play serious detrimental effects on cardiovascular health. This review aims to explore the available literature on breast cancer therapy-induced side effects on heart and vessels, illustrating the molecular mechanisms of cardiotoxicity known so far. Read More

View Article and Full-Text PDF

Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines.

Curr Oncol 2022 Jun 1;29(6):4020-4033. Epub 2022 Jun 1.

Department of Obstetrics and Gynecology, Faculty of Medicine, Shimane University, Izumo 693-8501, Japan.

Few studies have reported hormonal agent use in the treatment of low-grade serous ovarian carcinomas (LGSOCs), which are chemoresistant. Considering the need for novel effective therapies, we investigated the hormone receptor expression and hormonal inhibition efficacy in LGSOCs. Using immunohistochemistry, we assessed the estrogen receptor (ER) expression status in 33 cases of histologically confirmed serous ovarian tumors, including 10, 11, and 12 cases of LGSOCs, serous borderline tumors (SBTs), and serous cystadenomas (SCAs), respectively. Read More

View Article and Full-Text PDF

Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan.

Breast Cancer 2022 Jun 22. Epub 2022 Jun 22.

Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8606, Japan.

Background: Male breast cancer (MBC) is rare; however, its incidence is increasing. There have been no large-scale reports on the clinicopathological characteristics of MBC in Japan.

Methods: We investigated patients diagnosed with breast cancer in the Japanese National Clinical Database (NCD) between January 2012 and December 2018. Read More

View Article and Full-Text PDF

Effects of iron modulation on mesenchymal stem cell-induced drug resistance in estrogen receptor-positive breast cancer.

Oncogene 2022 Jun 22. Epub 2022 Jun 22.

Department of Biomedical Engineering, University of Michigan, 2200 Bonisteel, Blvd., Ann Arbor, MI, 48109-2099, USA.

Patients with estrogen receptor-positive (ER+) breast cancer, the most common subtype, remain at risk for lethal metastatic disease years after diagnosis. Recurrence arises partly because tumor cells in bone marrow become resistant to estrogen-targeted therapy. Here, we utilized a co-culture model of bone marrow mesenchymal stem cells (MSCs) and ER+ breast cancer cells to recapitulate interactions of cancer cells in bone marrow niches. Read More

View Article and Full-Text PDF

Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting.

Cell Rep Med 2022 Jun;3(6):100664

University of California, San Francisco, Department of Hematology Oncology and Surgery, Helen Diller Comprehensive Cancer Center, San Francisco, CA 94143, USA; University of California, San Francisco, Department of Surgery and Helen Diller Comprehensive Cancer Center, San Francisco, CA 94143, USA. Electronic address:

First-line CDK4/6 inhibitor ribociclib plus letrozole improves survival in the metastatic setting, but lack of accrual of African American women is a shortcoming. Predicting benefit in the early-stage setting and diverse enrollment in trials need to be priorities.. Read More

View Article and Full-Text PDF

Formononetin regulates endothelial nitric oxide synthase to protect vascular endothelium in deep vein thrombosis rats.

Int J Immunopathol Pharmacol 2022 Jan-Dec;36:3946320221111117

Yantai Raphael Biotechnology Co.,Ltd, Yantai, China.

Objective: Formononetin is a bioactive isoflavone that has numerous medicinal benefits. We explored the feasibility and its mechanism of formononetin on treating acute deep vein thrombosis (DVT) in rats.

Materials And Methods: Inferior vena cava (IVC) stenosis was performed to establish the DVT rat model. Read More

View Article and Full-Text PDF

New approaches to endocrine therapy in ER-positive, HER2-negative breast cancer.

Erika P Hamilton

Clin Adv Hematol Oncol 2022 06;20(6):356-358

Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee.

View Article and Full-Text PDF

Hormone therapy and fracture rates among postmenopausal women: results from the Women's Interagency HIV Study.

AIDS 2022 Jun 23. Epub 2022 Jun 23.

Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.

Background: Fracture rates have been reported to be higher among older women living with HIV (WLWH) than HIV- women. Hormone therapy with estrogen can reduce vasomotor symptoms (VMS) associated with menopause and prevent fractures. As data are limited on the benefits of hormone therapy use in WLWH, we examined associations of hormone therapy, use and fractures. Read More

View Article and Full-Text PDF

Non obvious diagnosis and breast development in pure gonadal dysgenesis.

Ginekol Pol 2022 Jun 22. Epub 2022 Jun 22.

Department of Gynecological Endocrinology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.

< span lang="EN-US" style="font-size: 12.0pt; line-height: 150%; font-family: 'Times New Roman',serif;" > Pure gonadal dysgenesis is a situation when the karyotype is 46, XY, but for various reasons there is a disorder of differentiation of Wolffian and Mullerian structures and in consequence the phenotype is female. It is known that abdominal gonads and the presence of Y chromosome allow to qualify this condition as a high risk of tumor. Read More

View Article and Full-Text PDF

Novel applications of molecular imaging to guide breast cancer therapy.

Cancer Imaging 2022 Jun 21;22(1):31. Epub 2022 Jun 21.

Department of Radiology, Hospital of the University if Pennsylvania, 3400 Spruce Street, Philadelphia, PA, 19104, USA.

The goals of precision oncology are to provide targeted drug therapy based on each individual's specific tumor biology, and to enable the prediction and early assessment of treatment response to allow treatment modification when necessary. Thus, precision oncology aims to maximize treatment success while minimizing the side effects of inadequate or suboptimal therapies. Molecular imaging, through noninvasive assessment of clinically relevant tumor biomarkers across the entire disease burden, has the potential to revolutionize clinical oncology, including breast oncology. Read More

View Article and Full-Text PDF

Estrogen replacement therapy: effects of starting age on final height of girls with chronic kidney disease and short stature.

BMC Pediatr 2022 Jun 21;22(1):355. Epub 2022 Jun 21.

Department of Pediatrics, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Introduction: We investigated the age of starting Estrogen replacement therapy as a key parameter for reaching near normal Final Height (FH) in Chronic Kidney Disease (CKD) girls with growth retardation.

Method: This open label, quasi-experimental designed and matched controlled clinical trial was performed on CKD girls with short stature and later onset of puberty or delayed puberty according to clinical and laboratory investigations. Participants of group 1 and 2 had been treated with Growth Hormone (GH), and Ethinyl Estradiol (EE). Read More

View Article and Full-Text PDF